Sherry Guo Email

VP Analytical Development and QC . Vaxcyte

Current Roles

Employees:
323
Revenue:
$17.1M
About
Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company's cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte's proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).
Vaxcyte Address
825 Industrial Road
Foster City, CA
United States
Vaxcyte Email

Past Companies

VaxcyteVP of Analytical Development and QC
Vaxcyte IncSr Director of Analytical Development & QC
GenentechHead of Global Analytical Science and Technology, Analytical Chemistry & Bioassay

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.